Around 75% of all breast cancers are positive for the Estrogen Receptor (ER), which is considered the main driver of the disease. In a siRNA screen targeting all 781 E1, E2 and E3 ligases throughout the human genome, we set out to discover novel regulators of ER stability. We identified TRIM33 as a crucial factor to regulate ER levels and activity. We aim to unravel the biological interplay between ER function and TRIM33, and explore how this interaction can be therapeutically exploited using novel inhibitors.
Defining the role of TRIM33 in hormone- dependent breast cancer